A Study of LX107 Gene Therapy in AIPL1-IRD Patients

This study tests a gene therapy (LX107) for people with a rare inherited eye condition called AIPL1-associated inherited retinal dystrophy, which causes progressive vision loss due to a faulty gene. The therapy aims to deliver a working copy of the gene directly into the eye. **You may be eligible if...** - You are 4 years old or older - You have been diagnosed with inherited retinal dystrophy caused by mutations in both copies of the AIPL1 gene, confirmed by genetic testing - The vision in your study eye is significantly reduced (visual acuity of 0.3 or less on standard testing) - You or your guardian can consent to long-term follow-up **You may NOT be eligible if...** - You do not have confirmed AIPL1 gene mutations - Your eye has certain structural conditions that could affect the safety or success of the injection - You are unable to comply with long-term follow-up requirements Talk to your doctor to see if this trial is right for you.